Faeth Therapeutics, Inc. (FTH) Key Metrics
FTH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $485.8M
- Enterprise value
- $630.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.7
- EV / EBITDA
- 1.4
- Dividend yield
- —
- Beta
- −0.29
FTH key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsFTH returns How much profit the business earns on the capital it uses.
FTH financial health Debt, liquidity and how easily interest is covered.
FTH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
FTH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
FTH cash returned to shareholders
FTH key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Share price at fiscal year-end | $10.67 | $9.80 | $13.84 | $29.80 | $116.00 | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −74.0% | −58.4% | −40.5% | −38.9% | −45.3% | — | — | — |
| Return on invested capital (ROIC) | — | −801.5% | −605.6% | — | — | — | — | — |
| Return on assets (ROA) | −61.8% | −50.4% | −35.4% | −35.8% | −42.1% | −177.5% | — | −704.8% |
| Return on tangible assets | −92.1% | −66.5% | −45.9% | −41.0% | −24.0% | −93.8% | — | −704.8% |
| Financial health | ||||||||
| Total debt | $1.5M | $3.8M | $6.2M | $8.0M | $2.4M | $685,000 | $16.1M | $4.7M |
| Cash & short-term investments | $21.2M | $41.3M | $65.8M | $107.1M | $147.6M | $16.6M | $251,000 | $653,000 |
| Net debt | −$19.7M | −$37.5M | −$59.5M | −$99.1M | −$145.3M | −$15.9M | $15.8M | $4.1M |
| Debt / equity | 0.08 | 0.10 | 0.10 | 0.08 | 0.02 | 0.04 | — | — |
| Debt / assets | 0.07 | 0.08 | 0.08 | 0.07 | 0.02 | 0.03 | 13.19 | 2.57 |
| Current ratio | 5.06 | 7.70 | 11.92 | 11.98 | 30.38 | 4.16 | 0.02 | 0.48 |
| Quick ratio | 5.06 | 7.70 | 11.92 | 11.98 | 30.38 | 4.16 | 0.02 | 0.48 |
| Interest coverage | -696.5 | -351.8 | -257.4 | -224.3 | -55.9 | -11.5 | -5.5 | -39.0 |
| Working capital | $17.3M | $36.5M | $61.6M | $99.5M | $143.7M | $15.2M | −$21.2M | −$1.4M |
| Invested capital | −$1.1M | $896,000 | $5.3M | $4.3M | $1.2M | −$18,000 | −$52.9M | −$49.4M |
| Tangible asset value | $18.6M | $38.4M | $64.9M | $103.4M | $146.5M | $15.9M | −$68.7M | −$53.5M |
| Net current asset value | $17.2M | $35.0M | $57.8M | $93.6M | $141.8M | $14.5M | −$69.4M | −$54.0M |
| Capital allocation | ||||||||
| Share buybacks (net) | $1,000 | $0 | $10.4M | $0 | — | — | — | — |
| Capex / depreciation | 0.12 | 0.11 | 0.13 | 0.24 | 2.96 | 5.77 | 0.73 | 0.70 |
| Efficiency | ||||||||
| Days payables outstanding | — | 641.9 | 1,971.1 | 699.4 | 1,688.6 | 6,403.2 | 11,397.5 | 9,191.4 |
| Payables turnover | — | 0.57 | 0.19 | 0.52 | 0.22 | 0.06 | 0.03 | 0.04 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $466,500 | $969,000 | $3.1M | $3.5M | $3.2M | $3.7M | $2.3M | $1.1M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from FTH's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
FTH valuation and financial ratios
Faeth Therapeutics earned a return on equity of −74.0% in fiscal 2025. It ended the year with $1.5 million of debt and $21.2 million in cash and short-term investments, a net cash position of $19.7 million. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the FTH income statement, the FTH chart for price history, or the FTH stock overview for the latest quote and news.
FTH key metrics FAQ
What is Faeth Therapeutics's return on equity?
Faeth Therapeutics's return on equity (ROE) was −74.0% in fiscal 2025: net income of -$21.1 million on average shareholders' equity of $28.5 million.
How much debt does Faeth Therapeutics have?
Faeth Therapeutics had total debt of $1.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.08 and more cash than debt.
Does Faeth Therapeutics buy back its shares?
Yes. Faeth Therapeutics spent $0.0 million on net share repurchases in fiscal 2025.
What is Faeth Therapeutics's current ratio?
Faeth Therapeutics's current ratio was 5.06 at the end of fiscal 2025: current assets were 5.06 times current liabilities.